News Medical on MSN
Medicaid Expansion Increases Access to HIV Prevention Medication for High-Risk Populations
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...
Rutgers Health researchers found that prescription rates for preexposure prophylaxis rose overall, but racial disparities ...
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...
Administration officials say South Africa has “significant means” to fund a promising new drug, lenacapavir, on its own. Critics call the move self-defeating.
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback